Selected investment case studies
How the work
actually gets done.
Seven assignments showing how scientific, legal, operating, and structural evidence was converted into decisions—and revised when the facts changed.
Navigate the cases
Different assets. One analytical discipline.
VaxGen
Leading a $20 million structured financing around the world’s first Phase III preventive HIV-vaccine program—and managing the security as the clinical and corporate thesis changed.
Situation & core question
VaxGen was funding two pivotal AIDSVAX programs before efficacy was known. The question was whether manufacturing and commercialization preparation could be financed while protecting against binary clinical risk, dilution, liquidity, and additional capital needs.
Diligence & underwriting
The work connected trial design, biological rationale, safety, regulatory pathway, manufacturing readiness, licensed technology, cash runway, and milestone timing. Scientific credibility had to be translated into an investable financing calendar.
Structure & execution
The investment firm led a $20 million Series A financing and supplied $15 million through 6% cumulative redeemable convertible preferred stock and warrants, with liquidation priority, redemption rights, anti-dilution protection, registration rights, and specified consent protections.
Evolution & risk management
The lead investor converted its preferred into common stock before the first pivotal readout. Both AIDSVAX trials later missed their primary efficacy endpoints, and VaxGen shifted toward biodefense. The case required security-level decisions as the original thesis changed fundamentally.
What it demonstrates
Direct origination and security design around a genuinely binary catalyst—plus the discipline to separate structural protection from the continuing need to reassess science, financing, liquidity, and strategy. The final position-level return is not stated because the surviving public record does not establish the complete exit.
Based on VaxGen SEC filings, contemporaneous reporting, government review, and transaction records. Certain portfolio-management details remain private.
Camp Lejeune
Building, financing, and repeatedly re-underwriting a portfolio of mass-tort claims as legal, scientific, operational, and timing assumptions evolved.
Situation & core question
The investable asset was a portfolio of contingent claims—not a conventional company or loan. The question was whether claims could be sourced, validated, acquired, financed, and monitored at a cost that left sufficient value after eligibility failures, fees, expenses, attrition, and delay.
Diligence & data
Claimant eligibility, presence and duration at Camp Lejeune, medical evidence, disease category, water and exposure information, filing status, representation, duplicate records, and documentation quality had to be normalized across sourced inventories.
Underwriting & execution
Claimant-level assumptions rolled into portfolio scenarios covering eligible-case conversion, recovery, fee sharing, acquisition cost, expenses, financing cost, duration, and concentration. Capital formation and funding timelines had to match acquisition and litigation needs.
Evolution & risk management
The model evolved with docket developments, exposure analysis, disease differentiation, secondary-market indications, claimant quality, and operational experience. Inventories were monitored through intake, validation, documentation, filing, and resolution stages.
What it demonstrates
How to turn a large, messy claimant population into an underwritten portfolio: define the asset, test the data chain, price attrition and time, evaluate vendors and counsel, structure funding, and revise valuation as facts change. The portfolio remains described as ongoing; no unverified return or recovery figure is published.
Counterparties, claimant information, current portfolio marks, and proprietary assumptions are omitted or generalized.
AFFF / PFAS
Underwriting evolving science, exposure, claimant selection, and litigation risk across multiple sourced inventories.
Situation & core question
Each claimant depended on a chain connecting disease, medical history, address or occupational history, exposure pathway, latency, competing causes, legal status, and supporting documents. The core question was which cohorts justified acquisition cost and development expense.
Diligence & data
Address histories were connected to water systems and other exposure pathways; disease categories, latency, medical records, and alternative causes were reviewed. Historical geography mattered because residence in an affected region did not establish identical exposure for every claimant.
Underwriting & execution
Valuation combined claimant screening with cohort assumptions for exposure strength, documentation, attrition, recovery, participation economics, costs, duration, financing expense, and concentration. Science and Rule 702/Daubert risk were modeled together with legal outcomes.
Evolution & risk management
New scientific, evidentiary, and docket developments changed which diseases and exposure pathways were attractive. Vendor conversion, duplicates, documentation status, counsel, geography, and theory concentration were monitored across the portfolio.
What it demonstrates
The integration of science, legal standards, historical exposure data, vendor operations, claimant evidence, and financial modeling—followed by the harder step of changing selection criteria and portfolio value when the evidence evolves.
The law-firm and sourcing counterparties remain unnamed pending a separate disclosure decision.
Entelos
Financing a predictive-biosimulation company with senior-secured convertible debt while underwriting its disease models as operating assets, intellectual property, and collateral.
Situation & core question
The investment firm committed $5 million to 10% senior-secured convertible debentures in December 2007 and June 2008. With an illiquid public stock, principal protection had to come from seniority, collateral, covenants, and recoverable model value—not an assumed equity exit.
Diligence & underwriting
Entelos’s computer-based disease models combined scientific literature, clinical data, biological pathways, and partner research. The work tested whether the models generated repeat revenue, reusable know-how, defensible intellectual property, and strategic value to pharmaceutical partners.
Structure & execution
The 10% debentures matured in December 2011, accreted interest for the first year, and were secured by company assets. Financial tests and restrictions on debt, equity financing, liens, cash flows, and asset sales preserved creditor control and restructuring leverage.
Evolution & risk management
When 2008 performance weakened, the thesis shifted from growth and conversion upside toward cash preservation, partner demand, asset coverage, and covenant enforcement. The company went private and restructured while strategic interest and third-party bids informed collateral analysis.
What it demonstrates
Hybrid underwriting across healthcare science, software economics, intellectual property, and private credit. The contemporaneous record establishes the restructuring posture but not the investment firm’s final repayment or realized return, so no unsupported outcome is claimed.
Based on a contemporaneous investment summary and corroborating public information concerning Entelos’s platform, partners, and financing.
ChromaVision Medical Systems
Leading a structured-equity financing for an automated cellular-imaging company, reducing exposure through active trading, and preserving value through a sponsor-supported restructuring.
Situation & core question
ChromaVision’s automated microscope and imaging software supported pathologist analysis across a growing test menu. The investor had to finance adoption while managing the possibility that customer utilization, receivables, operating controls, and cash needs would lag headline growth.
Diligence & underwriting
The analysis connected installed systems to utilization, fee-per-use revenue, disposables, working capital, regulatory progress, and operating leverage. Trading volume and stock borrow were underwritten before closing because hedging was part of the risk plan.
Structure & execution
The investor led a $12.5 million July 2001 financing of Series D 5% cumulative convertible preferred stock and warrants, with a $5 million lead position. Seniority, a three-year redemption, reset and anti-dilution provisions, warrants, and registration rights complemented active trading.
Evolution & risk management
Exposure was reduced immediately. When adoption disappointed, the stock fell and liquidity tightened. With the stock below the reset floor and new financing likely to trigger anti-dilution rights, the investment moved into a negotiation with Safeguard Scientifics, the company’s largest shareholder.
Outcome & what it demonstrates
Safeguard acquired most of the preferred, invested new common equity, and guaranteed additional debt. Harry’s contemporaneous record states that the investment firm received face value for the preferred, retained reset warrants, and earned approximately $1 million—nearly 20%—despite the common-equity collapse. It is a full-cycle example of structure, trading discipline, and negotiated exit working together.
Transaction terms and Safeguard’s restructuring are corroborated by ChromaVision SEC filings. The return is drawn from Harry’s contemporaneous investment record.
Healthcare E-Commerce Acquisition Platform
Months of operating, market, valuation, and capital-structure work on a fast-growing brand-acquisition platform—ending without an investment when the available security did not adequately protect the downside.
Situation & core question
The company acquired and developed healthcare-oriented e-commerce brands, combining medical and regulatory knowledge with Amazon, direct-to-consumer, advertising, sourcing, and product-development capabilities. The central question was whether its acquisition and optimization engine justified the valuation and whether an investable security could be structured around the existing leverage.
Diligence & data
The work separated an appealing healthcare narrative from the actual economic drivers: customer acquisition, marketplace ranking, advertising efficiency, conversion, repeat purchasing, procurement, inventory, brand extensions, and geographic expansion. Months of diligence examined acquisition sourcing, customer stickiness, contribution margins, operating leverage, integration capacity, and the repeatability of the brand-improvement playbook.
Underwriting & capital structure
Management projected rapid growth through existing brands and repeated acquisitions. The analysis tested how organic growth, purchased revenue, advertising spend, working capital, earn-outs, debt drawdowns, interest expense, liquidity covenants, and future equity requirements interacted. Strong operating momentum could be real without making the full acquisition forecast—or the proposed security—safe.
Structure & decision
The available preferred equity had liquidation priority over common stock but remained structurally behind a secured lender with claims on the operating assets. Alternative protections were explored, yet the financing requirements and existing collateral package meant a new investment would remain materially exposed in a downside case. The transaction was not completed.
What it demonstrates
Not every valuable assignment ends with capital deployment. This case shows the ability to dig deeply into a fast-growing operating platform, identify the real value drivers beneath the sector story, challenge acquisition-led projections, trace creditor priority, and allow capital structure to override enthusiasm for the business. The result was disciplined non-investment when the security could not be made commensurate with the risk.
The company, investment platform, counterparties, valuation, and confidential financing terms are intentionally omitted. No investment was completed.
Specialty Pharmaceutical Acquisition
Supporting a third-party private-equity firm with product-level commercial diligence, scenario valuation, pipeline analysis, and repeated multi-hour investment presentations.
Situation & core question
The target combined two principal marketed products, a declining third product, and a development-stage pulmonary arterial hypertension program. The acquisition thesis depended on using cash flow from the commercial portfolio to support a potentially valuable clinical asset. The question was what the business was worth once generic entry, competitive intensity, geographic uncertainty, development cost, and time were treated realistically.
Product-level diligence
The work decomposed the company rather than applying one multiple to consolidated EBITDA. An established obesity product was assessed against generics, GLP-1 therapies, price-sensitive patients, and patients unable to remain on GLP-1s. A pancreatic-enzyme product was evaluated as a trusted but largely commoditized therapy competing through price, channel execution, positioning, and patient or prescriber loyalty.
Pipeline & capital allocation
The PAH program was analyzed separately as a risk-adjusted option: mechanism, regulatory pathway, orphan positioning, competing therapies, development cost, launch timing, pricing, market role, and cost of capital. The analysis made explicit that capital used to preserve the development option could not simultaneously support marketed products, acquisitions, or distributions.
Scenario valuation
Management, base, bear, and bull cases varied product growth, generic and international performance, EBITDA margins, operating expense, launch timing, and residual cash-flow assumptions. Marketed-product values ranged from approximately $167 million to $312 million. Separate pipeline cases ranged from roughly $41 million under a delayed path to approximately $98 million under a more favorable path.
Presentation & decision support
The analysis was prepared for a third-party private-equity firm and presented multiple times in sessions lasting several hours. The work required explaining and defending product assumptions, valuation sensitivities, scientific risk, commercial competition, capital allocation, and the transaction implications of changing facts—not simply delivering a static model.
Evolution & structure
The view became more cautious as generic pressure, overseas challenges, geopolitics, tariffs, revised expectations, and margin vulnerability reduced visibility. The conclusion was that uncertainty should affect both purchase consideration and structure, with contingent value, milestones, or other risk-sharing mechanisms used to bridge disagreement.
What it demonstrates
This case demonstrates third-party investment judgment: mastering a complex pharmaceutical target, valuing marketed and clinical assets differently, building transparent scenarios, responding to new information, and defending conclusions before a sophisticated private-equity audience. It connects science, commercial analysis, financial modeling, transaction structure, and executive communication in one decision process.
The private-equity client, target company, advisers, proposed transaction structure, and ultimate acquisition outcome are intentionally omitted.
Certain names, counterparties, transaction terms, proprietary assumptions, and investment conclusions have been omitted or generalized for confidentiality. These case studies describe historical analytical experience and are not offers, recommendations, or indications of future results.